clinical trial · NCT07344376
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)
MPS IIHunter Syndrome (MPS II)Hunter SyndromeHunteraseGC1111Hunterase
brief summary
The objective of this study is to assess the long-term safety and efficacy of Hunterase for approximately 1 year in subjects who completed the end of study (EOS) visit (Visit 54) tests in the Phase 3 Hunterase study and patients who received Hunterase for more than 6 months
started
May 23, 2018
primary completion
Dec 30, 2022
completion
Dec 30, 2022
last updated
Jan 15, 2026
official title
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) in Patients With Hunter Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol